Krystal Historical Balance Sheet

KRYS Stock

USD 196.91 0.39 0.20%

Trend analysis of Krystal Biotech balance sheet accounts such as Total Current Liabilities of 34.7 M provides information on Krystal Biotech's total assets, liabilities, and equity, which is the actual value of Krystal Biotech to its prevalent stockholders. By breaking down trends over time using Krystal Biotech balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Krystal Biotech latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Krystal Biotech is a good buy for the upcoming year.

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Krystal Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For more information on how to buy Krystal Stock please use our How to Invest in Krystal Biotech guide.

About Krystal Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Krystal Biotech at a specified time, usually calculated after every quarter, six months, or one year. Krystal Biotech Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Krystal Biotech and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Krystal currently owns. An asset can also be divided into two categories, current and non-current.

Krystal Biotech Balance Sheet Chart

At this time, Krystal Biotech's Liabilities And Stockholders Equity is comparatively stable compared to the past year. Capital Surpluse is likely to gain to about 886.9 M in 2024, despite the fact that Net Debt is likely to grow to (332.7 M).

Total Assets Short Long Term Debt Total Total Current Liabilities Total Stockholder Equity

Add Fundamental

Total Assets

Total assets refers to the total amount of Krystal Biotech assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Krystal Biotech books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Krystal Biotech balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Krystal Biotech are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Most accounts from Krystal Biotech's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Krystal Biotech current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Krystal Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For more information on how to buy Krystal Stock please use our How to Invest in Krystal Biotech guide.At this time, Krystal Biotech's Liabilities And Stockholders Equity is comparatively stable compared to the past year. Capital Surpluse is likely to gain to about 886.9 M in 2024, despite the fact that Net Debt is likely to grow to (332.7 M).

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	8.0M	8.9M	8.1M	7.6M
Total Assets	626.3M	558.5M	818.4M	859.3M

Short Long Term Debt Total Total Assets

Krystal Biotech balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Property Plant Equipment	Retained Earnings Total Equity	Net Invested Capital
Total Assets		0.81	0.93	0.99	1.0	0.77	0.99	0.96	-0.93	-0.95	0.7	0.86	0.98	0.92	0.9	-0.73	0.82	0.99	0.83	0.99	0.98	0.97	1.0	0.97	-0.95	0.93
Short Long Term Debt Total	0.81		0.61	0.85	0.81	0.76	0.85	0.76	-0.85	-0.77	0.69	0.86	0.73	0.86	0.88	-0.38	0.74	0.84	0.93	0.8	0.84	0.75	0.83	0.73	-0.86	0.81
Other Current Liab	0.93	0.61		0.93	0.93	0.61	0.9	0.97	-0.74	-0.96	0.6	0.66	0.98	0.8	0.78	-0.74	0.8	0.93	0.62	0.95	0.93	0.98	0.9	0.98	-0.88	0.86
Total Current Liabilities	0.99	0.85	0.93		0.98	0.73	0.98	0.98	-0.89	-0.97	0.72	0.83	0.98	0.91	0.91	-0.68	0.86	0.99	0.84	0.99	1.0	0.98	0.98	0.98	-0.97	0.93
Total Stockholder Equity	1.0	0.81	0.93	0.98		0.77	0.99	0.96	-0.93	-0.95	0.7	0.87	0.98	0.92	0.9	-0.73	0.82	0.99	0.82	0.99	0.98	0.96	1.0	0.97	-0.95	0.93
Other Liab	0.77	0.76	0.61	0.73	0.77		0.8	0.67	-0.85	-0.69	0.56	0.83	0.66	0.8	0.82	-0.45	0.48	0.78	0.7	0.74	0.7	0.66	0.81	0.66	-0.76	0.71
Net Tangible Assets	0.99	0.85	0.9	0.98	0.99	0.8		0.96	-0.94	-0.94	0.79	0.89	0.96	0.95	0.94	-0.63	0.86	1.0	0.87	0.98	0.98	0.95	0.99	0.95	-0.98	0.95
Property Plant And Equipment Net	0.96	0.76	0.97	0.98	0.96	0.67	0.96		-0.81	-0.99	0.68	0.75	0.99	0.87	0.87	-0.68	0.87	0.97	0.74	0.98	0.98	1.0	0.94	1.0	-0.95	0.91
Net Debt	-0.93	-0.85	-0.74	-0.89	-0.93	-0.85	-0.94	-0.81		0.8	-0.72	-0.97	-0.85	-0.92	-0.91	0.6	-0.73	-0.92	-0.91	-0.9	-0.88	-0.81	-0.95	-0.81	0.89	-0.89
Retained Earnings	-0.95	-0.77	-0.96	-0.97	-0.95	-0.69	-0.94	-0.99	0.8		-0.61	-0.74	-0.96	-0.88	-0.89	0.66	-0.86	-0.96	-0.73	-0.97	-0.97	-0.99	-0.93	-0.99	0.94	-0.91
Accounts Payable	0.7	0.69	0.6	0.72	0.7	0.56	0.79	0.68	-0.72	-0.61		0.74	0.7	0.77	0.72	-0.15	0.79	0.75	0.82	0.67	0.73	0.67	0.69	0.63	-0.83	0.75
Cash	0.86	0.86	0.66	0.83	0.87	0.83	0.89	0.75	-0.97	-0.74	0.74		0.78	0.96	0.93	-0.41	0.76	0.87	0.95	0.83	0.83	0.74	0.89	0.74	-0.87	0.91
Non Current Assets Total	0.98	0.73	0.98	0.98	0.98	0.66	0.96	0.99	-0.85	-0.96	0.7	0.78		0.88	0.85	-0.72	0.85	0.98	0.76	0.98	0.98	0.99	0.96	0.99	-0.94	0.92
Cash And Short Term Investments	0.92	0.86	0.8	0.91	0.92	0.8	0.95	0.87	-0.92	-0.88	0.77	0.96	0.88		0.98	-0.43	0.88	0.94	0.92	0.91	0.91	0.87	0.93	0.86	-0.95	0.98
Common Stock Shares Outstanding	0.9	0.88	0.78	0.91	0.9	0.82	0.94	0.87	-0.91	-0.89	0.72	0.93	0.85	0.98		-0.42	0.87	0.93	0.9	0.9	0.9	0.86	0.92	0.85	-0.95	0.95
Long Term Debt Total	-0.73	-0.38	-0.74	-0.68	-0.73	-0.45	-0.63	-0.68	0.6	0.66	-0.15	-0.41	-0.72	-0.43	-0.42		-0.32	-0.66	-0.33	-0.73	-0.67	-0.69	-0.72	-0.73	0.51	-0.48
Non Current Liabilities Total	0.82	0.74	0.8	0.86	0.82	0.48	0.86	0.87	-0.73	-0.86	0.79	0.76	0.85	0.88	0.87	-0.32		0.86	0.82	0.85	0.88	0.87	0.8	0.84	-0.91	0.92
Capital Surpluse	0.99	0.84	0.93	0.99	0.99	0.78	1.0	0.97	-0.92	-0.96	0.75	0.87	0.98	0.94	0.93	-0.66	0.86		0.85	0.99	0.99	0.97	0.99	0.97	-0.98	0.94
Other Current Assets	0.83	0.93	0.62	0.84	0.82	0.7	0.87	0.74	-0.91	-0.73	0.82	0.95	0.76	0.92	0.9	-0.33	0.82	0.85		0.8	0.84	0.74	0.84	0.72	-0.88	0.88
Other Stockholder Equity	0.99	0.8	0.95	0.99	0.99	0.74	0.98	0.98	-0.9	-0.97	0.67	0.83	0.98	0.91	0.9	-0.73	0.85	0.99	0.8		0.99	0.98	0.99	0.98	-0.95	0.93
Total Liab	0.98	0.84	0.93	1.0	0.98	0.7	0.98	0.98	-0.88	-0.97	0.73	0.83	0.98	0.91	0.9	-0.67	0.88	0.99	0.84	0.99		0.98	0.97	0.98	-0.97	0.94
Property Plant And Equipment Gross	0.97	0.75	0.98	0.98	0.96	0.66	0.95	1.0	-0.81	-0.99	0.67	0.74	0.99	0.87	0.86	-0.69	0.87	0.97	0.74	0.98	0.98		0.94	1.0	-0.94	0.91
Total Current Assets	1.0	0.83	0.9	0.98	1.0	0.81	0.99	0.94	-0.95	-0.93	0.69	0.89	0.96	0.93	0.92	-0.72	0.8	0.99	0.84	0.99	0.97	0.94		0.95	-0.95	0.93
Property Plant Equipment	0.97	0.73	0.98	0.98	0.97	0.66	0.95	1.0	-0.81	-0.99	0.63	0.74	0.99	0.86	0.85	-0.73	0.84	0.97	0.72	0.98	0.98	1.0	0.95		-0.93	0.9
Retained Earnings Total Equity	-0.95	-0.86	-0.88	-0.97	-0.95	-0.76	-0.98	-0.95	0.89	0.94	-0.83	-0.87	-0.94	-0.95	-0.95	0.51	-0.91	-0.98	-0.88	-0.95	-0.97	-0.94	-0.95	-0.93		-0.95
Net Invested Capital	0.93	0.81	0.86	0.93	0.93	0.71	0.95	0.91	-0.89	-0.91	0.75	0.91	0.92	0.98	0.95	-0.48	0.92	0.94	0.88	0.93	0.94	0.91	0.93	0.9	-0.95

Click cells to compare fundamentals

Krystal Biotech Account Relationship Matchups

Krystal Biotech balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	209.0M	310.8M	626.3M	558.5M	818.4M	859.3M
Other Current Liab	19K	(3.2M)	16.2M	21.7M	26.0M	27.3M
Total Current Liabilities	3.3M	15.5M	25.7M	28.8M	33.1M	34.7M
Total Stockholder Equity	202.9M	292.1M	593.6M	522.2M	778.6M	817.6M
Net Tangible Assets	202.9M	292.1M	593.6M	522.2M	600.6M	630.6M
Property Plant And Equipment Net	11.2M	34.2M	119.6M	169.7M	168.2M	176.6M
Net Debt	(184.3M)	(256.7M)	(333.2M)	(153.0M)	(350.2M)	(332.7M)
Retained Earnings	(39.0M)	(71.2M)	(140.8M)	(280.8M)	(269.8M)	(256.3M)
Accounts Payable	724K	2.1M	8.4M	4.0M	1.8M	2.5M
Cash	187.5M	268.3M	341.2M	161.9M	358.3M	202.5M
Non Current Assets Total	13.1M	35.8M	184.0M	174.7M	230.4M	242.0M
Non Currrent Assets Other	1.5M	1.6M	74K	324K	263K	249.9K
Cash And Short Term Investments	193.7M	271.3M	438.1M	379.2M	532.2M	271.9M
Common Stock Shares Outstanding	15.9M	18.8M	22.2M	25.5M	27.8M	18.0M
Liabilities And Stockholders Equity	209.0M	310.8M	626.3M	558.5M	818.4M	859.3M
Non Current Liabilities Total	2.8M	3.3M	7.0M	7.4M	6.6M	4.0M
Capital Surpluse	133.2M	242.0M	363.3M	734.5M	844.7M	886.9M
Other Current Assets	2.2M	7.6M	8.3M	4.6M	6.7M	4.2M
Other Stockholder Equity	242.0M	363.3M	734.5M	803.7M	1.0B	1.1B
Total Liab	6.1M	18.8M	32.7M	36.2M	39.7M	41.7M
Property Plant And Equipment Gross	11.2M	34.2M	123.8M	176.5M	181.1M	190.1M
Total Current Assets	195.9M	275.1M	442.3M	383.8M	587.9M	617.3M
Accumulated Other Comprehensive Income	10K	6K	(163K)	(728K)	638K	669.9K
Property Plant Equipment	11.2M	30.9M	119.6M	169.7M	195.2M	204.9M
Other Assets	1.5M	4.9M	74K	324K	372.6K	354.0K
Short Term Investments	6.2M	3.0M	96.9M	217.3M	173.9M	182.5M
Net Invested Capital	202.9M	292.1M	593.6M	522.2M	778.6M	401.1M
Net Working Capital	192.6M	259.6M	416.5M	354.9M	554.8M	304.5M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Krystal Stock Analysis

When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Krystal Historical Balance Sheet

About Krystal Balance Sheet Analysis

Krystal Biotech Balance Sheet Chart

Total Assets

Total Current Liabilities

Total Stockholder Equity

Krystal Biotech balance sheet Correlations

Krystal Biotech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Krystal Biotech balance sheet Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Krystal Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Total Current Assets	+ 1.0	Total Stockholder Equity
Capital Surpluse	+ 1.0	Net Tangible Assets
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net

Property Plant Equipment	- 0.99	Retained Earnings
Property Plant And Equipment Gross	- 0.99	Retained Earnings
Retained Earnings	- 0.99	Property Plant And Equipment Net
Retained Earnings Total Equity	- 0.98	Capital Surpluse
Retained Earnings Total Equity	- 0.98	Net Tangible Assets
Retained Earnings Total Equity	- 0.97	Total Liab